The Alzheimer’s Drug Discovery Foundation (ADDF) is supporting scientists around the globe who are investigating novel drugs to prevent, treat and cure Alzheimer’s disease. The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. For clinical trial applications, The ADDF prioritizes novel drug candidates with the composition of matter intellectual property (IP) and repurposed or repositioned drugs with strategies to develop novel IP.
The Prevention Pipeline RFP supports:
- Studies of Cognitive Decline and Risk Reduction:
- Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA)
- Comparative Effectiveness Research
Eligibility
Funding is open to researchers and clinicians worldwide at:
- Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
- Biotechnology companies. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are both eligible.
The average Award is Up to $3,000,000 for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Funder: Alzheimer's Drug Discovery Foundation (ADDF)
URL: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-pipeline
Deadline: The letter of intent deadline is October 1, 2021
